Seeking Alpha

LSYMD's  Instablog

LSYMD
Send Message
I am an MD by background who runs a healthcare hedge fund. I worked as a sell-side medical analyst for 20 years, covering pharmaceuticals, medical devices, PBMs and drug distributors.
  • Pharmaceutical Stocks Continue To Act Well 3 comments
    Feb 25, 2014 2:39 PM | about stocks: GILD, GALT

    Within the medical stock subsectors, pharmaceutical stocks (especially those misnamed "biotech") act extremely well, notably those focused on hepatology, nephrology, oncology and orphan drug diseases. Significantly, I have noticed the highest number of 13G filings I have ever observed, which I think speaks favorably about the perceived prospects for these companies. Separately, I have discussed at length my enthusiasm for Hepatitis C-related companies; I am also positive on several of the companies involved with NASH , another liver disease that is increasingly becoming noticed by Wall Street. I have been recommending Galectin Therapeutics (NASDAQ:GALT) for the past year and am also intrigued with GENFIT. While some have called the top for these stocks, and I would not be surprised by periodic corrections as experienced in 2013, I believe that the trend remains from the "lower left to the upper right".

    Len

    Disclosure: I am long GILD, GALT, GNFTF.

    Themes: Pharmaceutical Stocks Stocks: GILD, GALT
Back To LSYMD's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (3)
Track new comments
  • Yu2014
    , contributor
    Comments (2) | Send Message
     
    Hello,

     

    I’m a french shareholder of Genfit, and I totally agree with your last sentence. I think that Genfit is far too undervalued if one considers the valuation of Intercept, the size of the NASH market, and the advantages that the GFT505 has over Intercept’s product.

     

    GFT505 has been proven to have no important side-effects : http://bit.ly/1fPDL6a
    That’s not the case for the Intercept’s product.

     

    As for the efficiency of GFT505, the 2b phase will end in October, 2014. The preclinical and the first clinical results seem to prove that it has great effects on multiple NASH factors. See that and that :
    http://bit.ly/LD5wFZ
    http://bit.ly/1dxLQKC

     

    Besides, one information that you may not have is that Genfit CEO, Jean-François Mouney, recently stated in a French interview that some American funds have been buying a lot of shares (10%-15% of the whole company, end of January) :
    http://bit.ly/1b2EiV7
    “Nos interlocuteurs font aujourd’hui partie du top 10 des investisseurs dans le domaine des biotechnologies, ce qui était encore difficile il y a un an. Notre visibilité a fait un bond en avant. J’ai été informé de l’entrée significative à notre capital de quelques fonds américains. Et nous pensons aujourd’hui que ces investisseurs américains représentent déjà de l’ordre de 10 à 15% du capital de Genfit en moins de trois semaines. “

     

    One additional information that you may not have is that Jean-François Mouney recently said that Genfit will be, by the end of spring, transferred from Alternext (French small caps market) to Euronext. It will greatly improve visibility, liquidity, … for investors.

     

    Sincerely yours,

     

    Yu
    26 Feb, 02:53 AM Reply Like
  • LSYMD
    , contributor
    Comments (71) | Send Message
     
    Author’s reply » Hi---many thanks for your comments. I agree that the safety profile of GFT505 looks excellent. The fact that it is a PPAR alpha-delta and not gamma may mean that it will not have the problems of drugs like pioglitazone. I am fortunate to own the stock in my fund. Len
    26 Feb, 10:18 AM Reply Like
  • danleeg
    , contributor
    Comments (29) | Send Message
     
    GFT505 looks like a yawn to me... Same MOAs as fenofibrate + rosiglitazone/pioglita... The other dual PPAR alpha-gamma agonist saroglitazar really has no efficacy advantages over fenofibrate + rosiglitazone/pioglita... on triglycerides/a1c. I think the PBMs will steer this towards the trash heap. It will probably get approval though
    9 Mar, 10:26 PM Reply Like
Full index of posts »
Latest Followers

StockTalks

More »

Latest Comments


Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.